Supplementary Material for: External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative Bacteremia
Adi Turjeman(Rabin Medical Center), L. Leibovici, Barak Pertzov(Tel Aviv University), Nasreen Hassoun‐Kheir(University Hospital of Geneva), Mario Sarti(Azienda Ospedaliero-Universitaria di Modena), Ebtehal Khazem(Rambam Health Care Campus), Dafna Yahav(Sheba Medical Center), Erica Bacca(University of Modena and Reggio Emilia), Ewa Baum, Erica Franceschini(University of Modena and Reggio Emilia), Marianna Meschiari(Azienda Ospedaliero-Universitaria di Modena), Noa Eliakim‐Raz(Tel Aviv University), Yaakov Dickstein(Tel Aviv Sourasky Medical Center), Tanya Babich(Unknown), Itamar Poran(Rabin Medical Center), Mical Paul(Technion – Israel Institute of Technology), Claudia Venturelli(Azienda Ospedaliero-Universitaria di Modena), Elias Maroun(Rambam Health Care Campus), Cristina Mussini(University of Modena and Reggio Emilia), Fidi Koppel(Rambam Health Care Campus), Jihad Bishara(Tel Aviv University), Roni Bitterman(Rambam Health Care Campus), Antonella Santoro(University of Modena and Reggio Emilia), Giovanni Dolci(University of Modena and Reggio Emilia), R. Nassar, A. Stern, Yael Dishon-Benatta(Technion – Israel Institute of Technology), Michael Raines, E. Goldberg
Cited by 0
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
|Clinical Microbiology and Infection|2021|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
|Nature Communications|2020|846
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727